Advertisement

Picture EBD Group BIO-Europe 2018 Copenhagen Denmark Partnerships 600x60px
Document › Details

Horizon Discovery Group plc. (10/6/14). "Press Release: Horizon Discovery Group Signs Co-Exclusive Commercial Agreement with Haplogen Genomics". Cambridge.

Region Region ALL
Organisations Organisation Horizon Discovery Group plc (LSE: HZD)
  Group Horizon Discovery (Group)
  Organisation 2 Haplogen Bioscience GmbH
Products Product cell line development (research assays)
  Product 2 cell line/system (research assays)
Person Person Disley, Darrin M. (Horizon Discovery 201109 CEO before Commercial Director)
     


Adds high-throughput, low cost CRISPR/Cas9 human haploid cell line generation service and extensive human haploid knock-out cell lines catalog


Horizon Discovery Group plc (LSE:HZD) (Horizon), a leading provider of research tools to support translational genomics and the development of personalized medicines, today announced it has entered a worldwide co-exclusive distribution agreement with Haplogen Genomics GmbH (Haplogen).

The agreement provides Horizon with access to a new high-throughput, affordable cell line engineering service. Haplogen’s extensive experience with haploid cell lines, along with a highly optimized production pipeline, allows knockouts for any non-essential gene to be generated at a throughput of hundreds of new isogenic cell lines per month. This highly efficient operation for the first time puts custom and validated human isogenic cell line pairs in the reach of all basic and translational scientists engaged in genomics and drug discovery research and development.

Horizon will also market Haplogen’s rapidly growing collection of over 700 human knockout cell lines, the largest collection of human cell lines deficient for the expression of single genes available, and more than 9,000 thousand gene trap mutants to the over 70,000 active academic research labs worldwide. Biotech and Pharma customers can access off the shelf or custom cell-lines through Horizon by signing a limited use label license for a one year term, while academic customers can access an unlimited term license at >80% discount. Combined these products and services potentially represent a significant revenue stream for Horizon, subject to market takeup.

Haplogen’s human cell lines carry only a single copy of each of its chromosomes and have been comprehensively characterized at the genomic, transcriptional and functional level, making them ideal for the of study a great variety of biological processes, such as signal transduction, cellular trafficking, DNA repair, cell cycle or host-pathogen interactions.

Dr Darrin M Disley, CEO of Horizon Discovery Group plc, commented: “This agreement represents a major opportunity for Horizon as we can now address the needs of the majority of academic research labs who have not historically been able to access our custom gene-editing services, but who now will be able to at a price that mirrors that of a typical pre-engineered catalogue item.”

Dr. Disley continued, “Haplogen’s products and services are highly complementary to our in-house portfolio, including our X-MAN™ range of diploid isogenic cell lines. This exclusive relationship supports Horizon’s goal of providing high quality product, service and R&D programs to customers engaged both in basic research and at every stage of translational genomics and personalized medicine, from sequence to treatment.”

Dr Thomas Moser, CEO of Haplogen Genomics, said: “We have been pleased with the success of the initial non-exclusive agreement and are very happy to now extend the range of Haplogen products and services offered through Horizon on a co-exclusive basis. Horizon’s global reputation within the industry and its commercial reach are increasing, and this amended marketing and distribution agreement will increase the impact of our products on translational genomics research.”

   
Record changed: 2017-04-02

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px

More documents for Horizon Discovery (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px




» top